After a traumatic event, injured workers may want to avoid the scene of the accident. But returning to work could help them heal.
Buprenorphine, a Schedule III controlled substance approved by the U.S. Food and Drug Administration (FDA), is increasingly being considered for pain management in workers' compensation cases. This partial opioid agonist offers a unique profile that balances effective pain relief with a lower risk of abuse and dependence compared to full opioid agonists.
Enhance your specialty bill review workflow with Enlyte's FairPay Flex. Learn how our dedicated team can resolve disputes and streamline processes.
Mitchell today announced the latest release of its Plugged-In: EV Collision Insights report. This edition features an overview of the most notable annual trends in battery electric vehicle (BEV), mild hybrid electric vehicle (MHEV) and plug-in hybrid electric vehicle (PHEV) collision claims. Following a second year of record sales for new cars with electrified powertrains, claims frequency for repairable BEVs rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively.
Claims frequency for collision-damaged, repairable battery electric vehicles (BEVs) rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively. CNBC reported that BEVs and hybrids represented 20% of all new U.S. vehicle sales in 2024, and Cox Automotive is predicting that number to climb to 25% in 2025 despite U.S. policy changes that could hinder BEV adoption.
In the complex world of medical bill review, specialty bill review stands out as a powerful tool for achieving significant savings. Chad Countryman, a seasoned account success director at Enlyte, shares his insights on how he coaches clients to understand and implement FairPay Flex effectively.
The 2025 CSN Collision Conference is an engaging and informative gathering for industry professionals.